Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia

BackgroundMicroRNAs (miRNAs) are small (19-22-nt) single-stranded noncoding RNA molecules whose deregulation of expression can contribute to human disease including the multistep processes of carcinogenesis in human. Circulating miRNAs are emerging biomarkers in many diseases and cancers such as type 2 diabetes, pulmonary disease, colorectal cancer, and gastric cancer among others; however, defining a plasma miRNA signature in acute myeloblastic leukemia (AML) that could serve as a biomarker for diagnosis or in the follow-up has not been done yet.MethodsTaqMan miRNA microarray was performed to identify deregulated miRNAs in the plasma of AML patients. Quantitative real-time RT-PCR was used to validate the results. Receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s).ResultsThe plasma expression level of let-7d, miR-150, miR-339, and miR-342 was down-regulated whilst that of let-7b, and miR-523 was up-regulated in the AML group at diagnosis compared to healthy controls. ROC curve analyses revealed an AUC (the areas under the ROC curve) of 0.835 (95% CI: 0.7119– 0.9581; P<0.0001) and 0.8125 (95% CI: 0.6796–0.9454; P=0.0005) for miR-150, and miR-342 respectively. Combined ROC analyses using these 2 miRNAs revealed an elevated AUC of 0.86 (95% CI: 0.7819–0.94; P<0.0001) indicating the additive effect in the diagnostic value of these 2 miRNAs. QRT-PCR results showed that the expression level of these two miRs in complete remission AML patients resembled that of healthy controls.ConclusionsOur findings indicated that plasma miR-150 and miR-342 are novel important promising biomarkers in the diagnosis of AML. These novel and promising markers warrant validation in larger prospective studies.

[1]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[2]  William Ignace Wei,et al.  Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue , 2008, Clinical Cancer Research.

[3]  H. Osada,et al.  MicroRNAs in biological processes and carcinogenesis. , 2007, Carcinogenesis.

[4]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[5]  Catalin Vasilescu,et al.  MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis , 2009, PloS one.

[6]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[7]  D. A. Stafford,et al.  Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. , 1997, Blood.

[8]  Laurence Zitvogel,et al.  Molecular Characterization of Dendritic Cell-Derived Exosomes , 1999, The Journal of cell biology.

[9]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[10]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[11]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[12]  C. Melief,et al.  B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.

[13]  G. Raposo,et al.  Accumulation of Major Histocompatibility Complex Class Ii Molecules in Mast Cell Secretory Granules and Their Release upon Degranulation Generation of Bmmcs Preparation of B Cells Reagents and Monoclonal Antibodies (mabs) Immunofluorescence Staining and Confocal Microscopy Pulse-chase# Labeling and , 2022 .

[14]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[15]  G. Schiller,et al.  Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. , 2008, Blood reviews.

[16]  M. Kudo,et al.  Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients , 2009, PloS one.

[17]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[18]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[19]  Ulus Atasoy,et al.  Circulating microRNAs in breast cancer and healthy subjects , 2009, BMC Research Notes.

[20]  D. Christiansen,et al.  Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities , 2002, Leukemia.

[21]  A. Régnault,et al.  TCR Activation of Human T Cells Induces the Production of Exosomes Bearing the TCR/CD3/ζ Complex1 , 2002, The Journal of Immunology.

[22]  E. Ng,et al.  Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening , 2009, Gut.

[23]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.

[24]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[25]  M. Spitz,et al.  Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  G. Raposo,et al.  Intestinal epithelial cells secrete exosome-like vesicles. , 2001, Gastroenterology.

[27]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[28]  G. Reid,et al.  Circulating microRNAs: Association with disease and potential use as biomarkers. , 2011, Critical reviews in oncology/hematology.

[29]  S. Kao,et al.  Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. , 2010, Oral diseases.

[30]  E. Estey,et al.  Adult acute myeloid leukemia. , 2006, Mayo Clinic proceedings.

[31]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[32]  K. Welte,et al.  Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. , 1995, The New England journal of medicine.

[33]  B. Pan,et al.  Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor , 1983, Cell.

[34]  Yoshiki Murakami,et al.  MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[35]  Piero Carninci,et al.  Site-specific DICER and DROSHA RNA products control the DNA damage response , 2012, Nature.

[36]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[37]  G. Raposo,et al.  Exosomes: a common pathway for a specialized function. , 2006, Journal of biochemistry.

[38]  P. M. Das,et al.  Downregulation of miR-342 is associated with tamoxifen resistant breast tumors , 2010, Molecular Cancer.

[39]  P. Selby,et al.  Proteomic analysis of melanoma‐derived exosomes by two‐dimensional polyacrylamide gel electrophoresis and mass spectrometry , 2004, Proteomics.

[40]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[41]  Yuchuan Huang,et al.  Circulating miRNAs: promising biomarkers of human cancer. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[42]  T. Leung,et al.  Detection and characterization of placental microRNAs in maternal plasma. , 2008, Clinical chemistry.

[43]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[44]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[45]  Hansjuerg Alder,et al.  The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. , 2009, Gynecologic oncology.

[46]  Zhaohui Huang,et al.  Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer , 2010, International journal of cancer.